BMC Cancer
(Jul 2023)
Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
- Yu-Yin Xu,
- Li Chen,
- Gui-Lan Wang,
- Jia-Ming Zhou,
- Yi-Xin Zhang,
- Yin-Ze Wei,
- Yuan-Yuan Zhu,
- Jing Qin
Affiliations
- Yu-Yin Xu
- Department of Pathological Anatomy, Nantong University
- Li Chen
- Department of Pathological Anatomy, Nantong University
- Gui-Lan Wang
- Department of Pathological Anatomy, Nantong University
- Jia-Ming Zhou
- Department of Pathological Anatomy, Nantong University
- Yi-Xin Zhang
- Department of Pathology, Affiliated Tumor Hospital, Nantong University
- Yin-Ze Wei
- Department of Pathology, Affiliated Tumor Hospital, Nantong University
- Yuan-Yuan Zhu
- Biomics (Nantong) Co., Ltd
- Jing Qin
- Department of Pathological Anatomy, Nantong University
- DOI
-
https://doi.org/10.1186/s12885-023-11135-3
- Journal volume & issue
-
Vol. 23,
no. 1
pp.
1
– 1
WeChat QR code
